Clinic-based evaluation of a point-of-care creatinine assay to screen for renal impairment among HIV-positive patients receiving tenofovir disoproxil fumarate

Clinic-based evaluation of a point-of-care creatinine assay to screen for renal impairment among HIV-positive patients receiving tenofovir disoproxil fumarate

Bibliographic Details
Main Authors:	Dorward, J, Yende-Zuma, N, Samsunder, N, Karim, Q, Drain, P, Garrett, N
Format:	Journal article
Language:	English
Published:	Lippincott, Williams and Wilkins 2018

Similar Items

Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate
by: Angsana Phuphuakrat MD, PhD, et al.
Published: (2022-10-01)

Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
by: Iman G.Al-Rakhat, et al.
Published: (2019-12-01)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
by: Aida N. Kawuma, et al.
Published: (2023-06-01)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
by: Chanie Wassner PharmD, BCCCP, BCIDP, et al.
Published: (2020-04-01)

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
by: Yim HJ, et al.
Published: (2022-09-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Safety of atazanavir/ritonavir with tenofovir disoproxil fumarate in HIV-infected adolescents
by: T. Bunupuradah, et al.
Published: (2014-04-01)

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
by: J Jones, et al.
Published: (2010-05-01)

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
by: J Jones, et al.
Published: (2010-05-01)

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate
by: Tim R. Cressey, et al.
Published: (2020-08-01)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018-04-01)

Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.
by: Jack E Heron, et al.
Published: (2023-01-01)

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
by: Pontrelli Giuseppe, et al.
Published: (2012-01-01)

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
by: Hyeyeon Hong, et al.
Published: (2024-01-01)

Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes
by: Ahmet Kayraldız, et al.
Published: (2016-06-01)

Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes
by: Kubra Kurt, et al.
Published: (2016-06-01)

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
by: Giacomo Stroffolini, et al.
Published: (2024-02-01)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
by: Linn Hermansson, et al.
Published: (2019-01-01)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
by: Young-Suk Lim, et al.
Published: (2023-10-01)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
by: He J, et al.
Published: (2023-06-01)

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis
by: Zekun Liu, et al.
Published: (2023-11-01)

Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: A systematic review
by: Bierhoff, M, et al.
Published: (2019)

Cost–utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
by: Dakin, H, et al.
Published: (2011)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
by: Kate Braithwaite, et al.
Published: (2021-08-01)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015-09-01)

Review: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B
by: Andrés Duarte-Rojo, et al.
Published: (2010-03-01)

Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
by: Young Chang, et al.
Published: (2021-11-01)

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults
by: Oche O. Agbaji MBBS, et al.
Published: (2019-01-01)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020-12-01)

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
by: Calvin Q Pan, et al.
Published: (2021-01-01)

Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
by: Calvin Q Pan, et al.
Published: (2014-01-01)

Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
by: Freeman W Chabala, et al.
Published: (2021-01-01)

Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice
by: Eungyeong Jang, et al.
Published: (2020-10-01)

Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
by: Fa- Da Wang, et al.
Published: (2023-09-01)

Fast and Ultrasensitive Electrochemical Detection for Antiviral Drug Tenofovir Disoproxil Fumarate in Biological Matrices
by: Jingyun Xiao, et al.
Published: (2022-12-01)

Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B
by: Daiki Aomura, et al.
Published: (2020-10-01)

New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate
by: Heba K. Ashour, et al.
Published: (2017-05-01)

Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
by: Ping Zhang, et al.
Published: (2018-08-01)